Methotrexate for Ocular Inflammatory Diseases

Ophthalmology

Volumn 116, Issue 11, 2009, Pages

  Gangaputra, Sapna ^a,b   Newcomb, Craig W ^d   Liesegang, Teresa L ^e   Kaçmaz, R Oktay ^f,g   Jabs, Douglas A ^b,c,g   Levy Clarke, Grace A ^h,i   Nussenblatt, Robert B ⁱ   Rosenbaum, James T ^e   Suhler, Eric B ^e,j   Thorne, Jennifer E ^b,c   Foster, C Stephen ^f,k   Kempen, John H ^d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h St Luke's Cataract and Laser Institute   (United States)

ⁱ NATIONAL EYE INSTITUTE   (United States)

^j PORTLAND VA MEDICAL CENTER   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; HUMAN; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALE; MUCOUS MEMBRANE PEMPHIGOID; PRIORITY JOURNAL; REMISSION; SCLERITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS;

EID: 70349295653     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.04.020     Document Type: Article

References (49)

1. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130 (2000) 492-513
2. Farber S., Diamond L.K., Mercer R.D., et al. Temporary remissions in acute leukemia in children produced by folic antagonist 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 238 (1948) 787-793
3. Wessels J.A., Huizinga T.W., and Guchelaar H.J. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 47 (2008) 249-255
4. Wong V.G., and Hersh E.M. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol 69 (1965) 279-293
5. Okada A.A. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13 (2005) 335-351
6. Kaplan-Messas A., Barkana Y., Avni I., and Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11 (2003) 131-139
7. Shah S.S., Lowder C.Y., Schmitt M.A., et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99 (1992) 1419-1423
8. Samson C.M., Waheed N., Baltatzis S., and Foster C.S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108 (2001) 1134-1139
9. Bom S., Zamiri P., and Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 9 (2001) 35-40
10. Malik A.R., and Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 89 (2005) 806-808
11. Foeldvari I., and Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 32 (2005) 362-365
12. Shetty A.K., Zganjar B.E., Ellis Jr. G.S., et al. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus 36 (1999) 125-128
13. Hemady R.K., Baer J.C., and Foster C.S. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 32 (1992) 241-252
14. Wallace C.A., Bleyer W.A., Sherry D.D., et al. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 32 (1989) 677-681
15. Dev S., McCallum R.M., and Jaffe G.J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 106 (1999) 111-118
16. McCluskey P., Chang J.H., Singh R., and Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 111 (2004) 796-801
17. Weinblatt M.E., Coblyn J.S., Fox D.A., et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312 (1985) 818-822
18. Lazar M., Weiner M.J., and Leopold I.H. Treatment of uveitis with methotrexate. Am J Ophthalmol 67 (1969) 383-387
19. Holz F.G., Krastel H., Breitbart A., et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1 (1992) 142-144
20. Wong V.G. Methotrexate treatment of uveal disease. Am J Med Sci 251 (1966) 239-241
21. Wong V.G. Immunosuppressive therapy of ocular inflammatory diseases. Arch Ophthalmol 81 (1969) 628-637
22. Hersh E.M., Wong V.G., and Freireich E.J. Inhibition of the local inflammatory response in man by antimetabolites. Blood 27 (1966) 38-48
23. Puchta J., Hattenbach L.O., and Baatz H. Intraocular levels of methotrexate after oral low-dose treatment in chronic uveitis. Ophthalmologica 219 (2005) 54-55
24. de Smet M.D., Stark-Vancs V., Kohler D.R., et al. Intraocular levels of methotrexate after intravenous administration. Am J Ophthalmol 121 (1996) 442-444
25. Kempen J.H., Daniel E., Gangaputra S., et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 15 (2008) 47-55
26. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 140 (2005) 509-516
27. Nussenblatt R.B., Palestine A.G., Chan C.C., and Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92 (1985) 467-471
28. Schimmer B.P., and Parker K.L. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill, New York 1587-1612 assoc eds.
29. Cox D.R., and Oakes D. Analysis of Survival Data (1984), Chapman & Hall, London 91-107
30. Galor A., Jabs D.A., Leder H.A., et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115 (2008) 1826-1832
31. Hoekstra M., Haagsma C., Neef C., et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31 (2004) 645-648
32. Heiligenhaus A., Mingels A., Heinz C., and Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 17 (2007) 743-748
33. Thorne J.E., Woreta F., Kedhar S.R., et al. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 143 (2007) 840-846
34. van Ede A.E., Laan R.F., Blom H.J., et al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 27 (1998) 277-292
35. Walker A.M., Funch D., Dreyer N.A., et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 36 (1993) 329-335
36. Tolman K.G., Clegg D.O., Lee R.G., and Ward J.R. Methotrexate and the liver. J Rheumatol Suppl 12 suppl (1985) 29-34
37. Hoekstra M., van Ede A.E., Haagsma C.J., et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003) 423-426
38. Lahdenne P., Rapola J., Ylijoki H., and Haapasaari J. Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy. J Rheumatol 29 (2002) 2442-2445
39. Suwa A., Hirakata M., Satoh S., et al. Rheumatoid arthritis associated with methotrexate-induced pneumonitis: improvement with i.v. cyclophosphamide therapy. Clin Exp Rheumatol 17 (1999) 355-358
40. Salaffi F., Manganelli P., Carotti M., et al. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 16 (1997) 296-304
41. Cottin V., Tebib J., Massonnet B., et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 109 (1996) 933-938
42. Hilliquin P., Renoux M., Perrot S., et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 35 (1996) 441-445
43. Doroshow J.H., Locker G.Y., Gaasterland D.E., et al. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer 48 (1981) 2158-2162
44. Clare G., Colley S., Kennett R., and Elston J.S. Reversible optic neuropathy associated with low-dose methotrexate therapy. J Neuroophthalmol 25 (2005) 109-112
45. Balachandran C., McCluskey P.J., Champion G.D., and Halmagyi G.M. Methotrexate-induced optic neuropathy. Clin Experiment Ophthalmol 30 (2002) 440-441
46. Baker K.B., Spurrier N.J., Watkins A.S., et al. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol 90 (2006) 1481-1485
47. Bawle E.V., Conard J.V., and Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 57 (1998) 51-55
48. Lewden B., Vial T., Elefant E., et al. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol 31 (2004) 2360-2365
49. Kempen J.H., Gangaputra S., Daniel E., et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146 (2008) 802-812